AI Article Synopsis

  • Marfan syndrome (MFS) is a rare genetic disorder that affects connective tissue, leading to serious complications like thoracic aortic aneurysms (TAA), which may require preventive surgery.
  • There is a need for non-invasive biomarkers and new therapeutic targets for MFS, as current monitoring methods involve complex imaging and are time-sensitive.
  • Recent studies using high-throughput platforms have identified potential biomarkers and therapeutic targets related to pathways involved in MFS, but further validation in large patient groups is needed to confirm their effectiveness.

Article Abstract

Marfan syndrome (MFS) is a rare congenital disorder of the connective tissue, leading to thoracic aortic aneurysms (TAA) and dissection, among other complications. Currently, the most efficient strategy to prevent life-threatening dissection is preventive surgery. Periodic imaging applying complex techniques is required to monitor TAA progression and to guide the timing of surgical intervention. Thus, there is an acute demand for non-invasive biomarkers for diagnosis and prognosis, as well as for innovative therapeutic targets of MFS. Unraveling the intricate pathomolecular mechanisms underlying the syndrome is vital to address these needs. High-throughput platforms are particularly well-suited for this purpose, as they enable the integration of different datasets, such as transcriptomic and epigenetic profiles. In this narrative review, we summarize relevant studies investigating changes in both the coding and non-coding transcriptome and epigenome in MFS-induced TAA. The collective findings highlight the implicated pathways, such as TGF-β signaling, extracellular matrix structure, inflammation, and mitochondrial dysfunction. Potential candidates as biomarkers, such as miR-200c, as well as therapeutic targets emerged, like Tfam, associated with mitochondrial respiration, or miR-632, stimulating endothelial-to-mesenchymal transition. While these discoveries are promising, rigorous and extensive validation in large patient cohorts is indispensable to confirm their clinical relevance and therapeutic potential.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11242319PMC
http://dx.doi.org/10.3390/ijms25137367DOI Listing

Publication Analysis

Top Keywords

coding non-coding
8
marfan syndrome
8
therapeutic targets
8
non-coding transcriptomic
4
transcriptomic landscape
4
landscape aortic
4
aortic complications
4
complications marfan
4
syndrome marfan
4
syndrome mfs
4

Similar Publications

Epigenetic Modulations of Non-Coding RNAs: A Novel Therapeutic Perspective in Sjӧgren's Syndrome.

Front Biosci (Landmark Ed)

November 2024

Department of Translational Biomedicine and Neuroscience (DiBraiN), Section of Human Anatomy and Histology, University of Bari "Aldo Moro", 70124 Bari, Italy.

Sjögren's syndrome (SS) is an autoimmune disease that can be classified as an epithelitis based on the immune-mediated attack directed specifically at epithelial cells. SS predominantly affects women, is characterized by the production of highly specific circulating autoantibodies, and the major targets are the salivary and lachrymal glands. Although a genetic predisposition has been amply demonstrated for SS, the etiology remains unclear.

View Article and Find Full Text PDF

Exploring the Regulatory Mechanism of CXCL16 Molecule-Related Antigen Presentation Using lncRNA-mRNA Co-Expression Network Analysis.

J Inflamm Res

December 2024

Beijing Institute of Heart, Lung and Blood Vessel Diseases, The Key Laboratory of Remodeling Cardiovascular Diseases, Ministry of Education, Collaborative Innovation Center for Cardiovascular Disorders, Beijing Anzhen Hospital, Capital Medical University, Beijing, People's Republic of China.

Aim: To investigate the regulatory mechanism of CXCL16 molecule-related ( extract-induced antigen presentation in a mouse asthma model based on the long non-coding RNA (lncRNA) and mRNA expression profile.

Methods: knockout mice and wild-type mice were administered with . extract by intratracheal instillations to induce asthma airway inflammation.

View Article and Find Full Text PDF

Dysregulated transfer RNA-derived small RNAs as potential gastric cancer biomarkers.

Exp Biol Med (Maywood)

December 2024

Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong University, Nantong, China.

Gastric cancer (GC) is the kind of carcinoma that has the highest rates of morbidity and death worldwide. In the early stages of GC, there is currently an absence of sensitive and specific biomarkers. The newly-discovered class of non-coding RNAs (ncRNAs) known as transfer RNA-derived small RNAs (tsRNAs) is highly expressed in bodily fluids and neoplastic cells.

View Article and Find Full Text PDF

Objective: Gastric cancer (GC) is a globally common cancer characterized by high incidence and mortality worldwide. Advances in the molecular understanding of GC provide promising targets for GC diagnosis and therapy. Long non-coding RNAs (lncRNAs) and their downstream regulators are regarded to be implicated in the progression of multiple types of malignancies.

View Article and Find Full Text PDF

Background: Prostate cancer (PCa) ranks as the second leading cause of cancer-related mortality among men. Long non-coding RNAs (lncRNAs) are known to play a regulatory role in the development of various human cancers. LncRNA MAFG-divergent transcript (MAFG-DT) was reported to play a crucial role in tumor progression of multiple human cancers, such as pancreatic cancer, colorectal cancer, bladder cancer, and gastric cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!